Article Text
Abstract
Background: Orchestration of two major classes of angiogenic factors—namely, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2)—has been shown to play a pivotal role in tumour angiogenesis, including hepatocellular carcinoma (HCC). However, few studies have focused on the direct interaction of these factors on in vivo tumour development and angiogenesis.
Aim: To examine the interaction between both factors in murine HCC.
Methods: We examined the combination effect of VEGF and Ang-2 overexpression by means of a combination of a retroviral tetracycline (tet) regulated gene manipulating system in vivo, by providing tet in the drinking water, and a conventional plasmid gene expression system.
Results: Neither Ang-2 nor VEGF overexpression induced proliferation of HCC cells in vitro. In vivo, although overexpression of Ang-2 did not increase tumour development, simultaneous expression of Ang-2 and VEGF synergistically augmented tumour growth and angiogenesis in murine HCC. Ang-2 plus VEGF induced tumour development was markedly attenuated by treatment with neutralising monoclonal antibodies against VEGF receptors. Ang-2 plus VEGF overexpression significantly increased the activities of matrix metalloproteinase (MMP)-2 and MMP-9 in the tumour. Suppression of intratumoral VEGF almost completely abolished this augmentation of MMPs.
Conclusions: These results suggest that Ang-2 synergistically augments VEGF mediated HCC development and angiogenesis. This proangiogenic activity was exerted only in the presence of VEGF, at least partly mediated via induction of MMP-2 and MMP-9 in the tumour.
- α-SMA, α smooth muscle actin
- Ang-1, Ang-2, angiopoietin 1 and 2, respectively
- APMA, p-aminophenylmercuric acetate
- bFGF, basic fibroblast growth factor
- BNL-HCC, BNL 1.7R1 hepatocellular carcinoma
- EC, endothelial cell
- ECM, extracellular matrix
- ELISA, enzyme linked immunosorbent assay
- HCC, hepatocellular carcinoma
- tet, tetracycline
- mAb, monoclonal antibody
- MMP, matrix metalloproteinase
- MVD, microvessel density
- PCR, polymerase chain reaction
- VEGF, vascular endothelial growth factor
- VEGFR-1, fms-like tyrosine kinase (flt-1)
- VEGFR-2, kinase-insert domain containing receptor/fetal liver kinase-1 (KDR/Flk-1)
- angiopoietin
- vascular endothelial growth factor
- hepatocellular carcinoma
- angiogenesis
- tumour growth
Statistics from Altmetric.com
- α-SMA, α smooth muscle actin
- Ang-1, Ang-2, angiopoietin 1 and 2, respectively
- APMA, p-aminophenylmercuric acetate
- bFGF, basic fibroblast growth factor
- BNL-HCC, BNL 1.7R1 hepatocellular carcinoma
- EC, endothelial cell
- ECM, extracellular matrix
- ELISA, enzyme linked immunosorbent assay
- HCC, hepatocellular carcinoma
- tet, tetracycline
- mAb, monoclonal antibody
- MMP, matrix metalloproteinase
- MVD, microvessel density
- PCR, polymerase chain reaction
- VEGF, vascular endothelial growth factor
- VEGFR-1, fms-like tyrosine kinase (flt-1)
- VEGFR-2, kinase-insert domain containing receptor/fetal liver kinase-1 (KDR/Flk-1)
Footnotes
-
Published online first 20 July 2005
-
Conflict of interest: None declared.